In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

Mechanism of action articles from across Nature Portfolio Mechanism of action describes the process by which a molecule, such as a drug, functions to produce a pharmacological effect.

This trial focused on patients with HER2-positive metastatic breast cancer who hadn't received any treatment other than a few with endocrine therapy for metastatic or advanced disease, and ...

China has taken a series of actions in the past week on counter-narcotics, in a sign of cooperation with U.S. demands for stronger action on the synthetic opioid fentanyl, a key irritant in the ...

Find out how Wegovy works for weight loss and the prevention of certain cardiovascular problems.

Bankrupt 23andMe is facing a lawsuit over its plans to sell customer genetic information. Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S ...

Mechanisms of disease articles from across Nature Portfolio The defects in molecular and cellular processes that constitute the triggers of specific pathologies are referred to as mechanisms of ...

Israel has launched what it is calling a "preemptive strike" against Iran and declared a state of emergency, according to Defense Minister Israel Katz.

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Cancer remains one of the leading causes of mortality worldwide, driving an ongoing search for more effective and selective ...

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer, including a 44% improvement in progression-free ...